FAVOUR: Frailty Assessment in Vascular Hot Clinic Setting - Feasibility and Prognostic Value

Sponsor
University of Glasgow (Other)
Overall Status
Recruiting
CT.gov ID
NCT06040658
Collaborator
(none)
150
1
19.6
7.6

Study Details

Study Description

Brief Summary

A single-centre prospective study of feasibility assessing the suitability of introducing routine frailty screening in a controlled, and reproducible, outpatient department setting for Vascular Surgery patients. This study will also perform head-to-head comparisons of the prognostic value of five frailty assessment tools, selected based on the previous demonstration of their popularity and familiarity within the speciality, their designs being based on different theories of frailty and that some are endorsed by local healthcare police. Inter-user variability (patient self assessment and clinician assessment will also be compared).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Frailty assessment
  • Diagnostic Test: Frailty assessment
  • Diagnostic Test: Frailty assessment
  • Diagnostic Test: Frailty assessment
  • Diagnostic Test: Frailty assessment

Detailed Description

This single-centre prospective cohort study of feasibility, is conducted in a rapid-referral vascular surgery clinic, serving a population of 2 million. Capax adults (>18years), attending clinic for any reason are eligible for inclusion. Five frailty assessments are completed at the clinic by patient (Rockwood Clinical Frailty Scale [CFS] and Frail NonDisabled Questionnaire [FiND]), clinician (CFS, Health care Improvement Scotland FRAIL Scale and 'Initial Clinical Evaluation') and researcher (11-item modified Frailty Index, mFI-11). Consistent with feasibility objectives, outcome measures include recruitment rates, frailty assessment completion rates, time-to-complete assessments and inter-rater variability. Electronic follow-up at 30-days and 1-year will assess home-time and mortality as prognostic indicators. Patients treated surgically/endovascularly will undergo additional 30-day and 1-year post-operative follow-up, outcome measures include: surgical procedure, mortality, complications (according to Clavien-Dindo Classification), length-of-stay, readmission rates, non-home discharge, home-time, higher social care requirements on discharge and amputation-free survival. Prognostic value will be compared by area under Receiver operator characteristic (ROC) curves. Continuous outcome variables will be analysed using Spearman's rank correlation coefficient. Inter-user agreement will be compared by percentage agreement in Cohen's Kappa coefficient.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Frailty Assessment in Vascular OUtpatients Review (FAVOUR Trial) - Comparing Feasibility and Prognostic Value of Commonly Used Assessments
Actual Study Start Date :
Mar 15, 2023
Actual Primary Completion Date :
Jul 17, 2023
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Vascular 'hot' clinic.

All adults (aged > 17 years) referred to an urgent-referral, consultant-led, Vascular Surgery outpatient clinic, who have capacity, will be eligible for inclusion in this study.

Diagnostic Test: Frailty assessment
Rockwood Clinical Frailty Scale

Diagnostic Test: Frailty assessment
Frail NonDisabled Questionnaire (FiND)

Diagnostic Test: Frailty assessment
Clinician's subjective 'end-of-bed' test

Diagnostic Test: Frailty assessment
Healthcare Improvement Scotland FRAIL Scale

Diagnostic Test: Frailty assessment
11-item modified Frailty Index (mFI-11)

Outcome Measures

Primary Outcome Measures

  1. Feasibility of implementing routine frailty assessment in a vascular clinic setting [During participant recruitment, over up to 4 months.]

    Proportion of patients recruited (Number of recruited patients/[number of patients attending clinic - number of ineligible patients]).

  2. Frailty assessment completion time [During participant recruitment, over up to 4 months.]

    Time taken to complete assessments (presented in seconds). The less time taken, the better.

  3. Frailty assessment completion rates [During participant recruitment, over up to 4 months.]

    Proportion of assessments with non-completion. Calculated by: number of incomplete frailty assessments/total number of recruited patients, the lower the value the better.

Secondary Outcome Measures

  1. Assessing the prognostic value of selected frailty assessment tools (Home time - all patients) [30-days and 1 year from recruitment/clinic attendance]

    'Home time': this describes the number of full days at home (not as a hospital inpatient) over the follow up periods. All recruited patients will undergo this follow-up.

  2. Assessing the prognostic value of selected frailty assessment tools (Mortality - all patients) [30-days and 1 year from recruitment/clinic attendance]

    Mortality: this will be calculated from date of recruitment. All recruited patients will undergo this follow-up.

  3. Assessing the peri-operative prognostic value of selected frailty assessment tools (Mortality) [30-days and 1 year from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: mortality. Proportion of patients dead at follow up.

  4. Assessing the peri-operative prognostic value of selected frailty assessment tools (Complications) [30-days and 1 year from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: post-operative complications (according to the Clavien-Dindo Classification).

  5. Assessing the peri-operative prognostic value of selected frailty assessment tools (Length of stay) [30-days and 1 year from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: length of hospital stay (full days). Calculated as number of full days as inpatient following admission for index procedure.

  6. Assessing the peri-operative prognostic value of selected frailty assessment tools (Readmission) [30-days from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: readmission rates (to any speciality). This will be calculated by the proportion of patients readmitted to hospital following index procedure/the number of patients undergoing surgical/endovascular treatment.

  7. Assessing the peri-operative prognostic value of selected frailty assessment tools (Non-home discharge) [30-days from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: non-home discharge. This will be calculated by the proportion of patients who are discharged to place of residence differing from their preoperative residence/total number of patients undergoing surgical/endovascular treatment. For example, from private residence preoperatively to care home.

  8. Assessing the peri-operative prognostic value of selected frailty assessment tools (Home time) [30-days and 1 year from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: home time. See outcome 4.

  9. Assessing the peri-operative prognostic value of selected frailty assessment tools (Social care requirements) [30-days from primary intervention offered following recruitment to study.]

    For patients offered endovascular/surgical/hybrid intervention: discharge with a higher level of social care requirements. This will be presented as the proportion of patients discharged with greater social care requirements than before their index admission/'total number of patients offered surgical or endovascular treatment. E.g., a patient is admitted preopertively with three times daily package of care and discharged with four times daily package of care

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults (aged 18 years or older)

  • Attending Vascular Hot Clinic

Exclusion Criteria:
  • Lacking capacity to provide informed consent

  • Parent clinical team feel frailty assessment not suitable

  • Non-English speaker without qualified translator present

  • Prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queen Elizabeth University Hospital Glasgow Lanarkshire United Kingdom G51 4TF

Sponsors and Collaborators

  • University of Glasgow

Investigators

  • Study Director: Quinn, University of Glasgow

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Silje Welsh, Principle Investigator, University of Glasgow
ClinicalTrials.gov Identifier:
NCT06040658
Other Study ID Numbers:
  • GN23CE014
First Posted:
Sep 15, 2023
Last Update Posted:
Sep 15, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2023